| EXC |
Report |
Q2 adj. operating EPS |
IN-LINE |
pred ~$0.44 vs. cons $0.43 |
MEDIUM |
| EXC |
Report |
H2 E EPS run-rate (seasonal glidepath) |
IN-LINE |
pred ~$1.35 (~47% of FY) vs. cons ~$1.34 |
MEDIUM |
| EXC |
Report |
Total operating revenue |
IN-LINE |
pred ~$5.6B vs. cons ~$5.5B |
LOW |
| EXC |
Guide |
FY2026 adjusted EPS guidance |
UNCHANGED |
guide $2.81–$2.91 (mid $2.86) vs. cons ~$2.86 (FY2026) |
HIGH |
| EXC |
Guide |
Long-term adjusted EPS CAGR |
UNCHANGED |
guide top-half of 5–7% (~6.5%) vs. cons ~6% (2025–2029) |
HIGH |
| EXC |
Guide |
Capital plan / rate-base CAGR |
UNCHANGED |
guide $41.7B plan, ~7.9% rate-base CAGR vs. cons ~$41.7B/~7.9% (2026–2029) |
MEDIUM |
| EXC |
Guide |
Pennsylvania (PECO) rate-case refiling / ROE-equity-layer risk |
UNKNOWN |
guide refiling timing TBD, ROE risk vs. cons ~9.5% ROE assumed (2026–2027) |
LOW |
| EXC |
Guide |
Maryland Pepco base-rate order |
UNKNOWN |
guide on $119.9M request, order due Aug vs. cons partial award ~$70–90M (2026Q3) |
LOW |
| EXC |
Return |
Day-1 residual (stock − beta × S&P 500) |
-0.6% |
— |
MEDIUM |
| EXC |
Return |
5-day cumulative residual |
-0.8% (STABILIZE) |
Seasonally tiny quarter with an in-line EPS and a clean reaffirmation of FY26 $2.81–$2.91 leaves out-period estimates essentially unchanged — no revision engine either way. Low-beta, decoupling-heavy name trades on the PA/MD affordability-regulatory narrative, not the print; residual drift is modest and mean-reverting. Mild negative skew from PA (PECO ROE/equity-layer and credit) and any soft Pepco MD signal caps upside, so the small day-1 dip largely holds rather than compounds — stabilize near flat. |
MEDIUM |